EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Companyâs products are based on two proprietary platform technologies: EyeGateâs first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (âCMHA-Sâ), a modified form of the natural polymer hyaluronic acid (âHAâ), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGateâs second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGateâs proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications. Source
No articles found.
Vivoo is a wellness assistant that consists of urinalysis test strips and a mobile...
Vivoo is a wellness assistant that consists of ...
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Join the National Investor Network and get the latest information with your interests in mind.